KELOWNA, BRITISH COLUMBIA - February 6, 2025 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...
Demonstrating the Potential of Innovative Exosome Technology to Mitigate Age-Related Neuroinflammation and Cognitive Decline EUNPYEONG-GU, SEOUL, SOUTH KOREA ...
Exosome-associated THSD7A is identified as a key trigger of filopodia formation in cancer cells and neurons, revealing a ...
RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU). Diabetic ...
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has ...
Advancing Exosome Technology to Address Inflammatory Conditions in Women's Health SEOUL, EUNPYEONG, SOUTH KOREA, July 9, 2025 /EINPresswire.com/ -- ILIAS Biologics ...
ShineOn's proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback